10-Year Data Supporting Long-Term Benefits
The latest study on Tecfidera revealed that over half of newly diagnosed patients treated with the drug did not relapse or progress for 6 years․ Data from the ongoing Phase 3 ENDORSE study showed the effectiveness and safety of continuous Tecfidera treatment over a decade, with low incidence rates․ Consult with a physician about the potential benefits and risks of this long-term MS treatment․
Official Guidelines on Long-Term Use
According to official guidelines, Tecfidera can be used for as long as it continues to provide clinical benefits and does not cause intolerable side effects․ It is crucial to monitor for benefits such as lesion control and lymphocyte levels to assess the ongoing efficacy of the treatment․ Consult with healthcare professionals for personalized recommendations on long-term Tecfidera use․
Potential Long-Term Risks
When considering the long-term use of Tecfiderait’s essential to be aware of potential risks․ One possible long-term risk associated with Tecfidera is the development of a low level of lymphocyteswhich can increase the risk of infections․ Monitoring lymphocyte levels and consulting with healthcare providers can help manage this risk effectively․
Study Findings on Discontinuation
Studies have shown that most patients who discontinue Tecfidera did so without triggering a rebound in disease activity․ This distinguishes Tecfidera from some other MS treatments that may lead to increased disease activity upon discontinuation․ It’s important to discuss any decision to discontinue Tecfidera with a healthcare provider to address potential implications․
Long-Term Impact on Disease Activity
New data analyses from Phase 3 studies show that long-term treatment with Tecfidera can lead to sustained benefits in disease activity measures for newly diagnosed MS patients․ The consistent low levels of disease activity demonstrate the positive impact of Tecfidera on controlling relapse and disability progression over the long term․
Leave a Reply